Main Topic Area
All Topic Areas
1 - 10 of 1034 more >>
Articles
1 - 1 of 1
- Antagon Injection Consumer Information
Antagon is used to inhibit premature ovulation in women undergoing fertility procedures. Women who have experienced a hypersensitivity reaction to gonadotropin-releasing hormone (GnRH) or any other GnRH-type drug. Women who suspect or know they are pregnant. A physician specializing in fertility treatment should prescribe Antagon. Before starting treatment with Antagon, pregnancy must be ruled out. General Precautions with Antagon: Patients with hypersensitivity to GnRH should be closely...
U.S. Food and Drug Administration
News
1 - 5 of 543 more >>
- Calcium Is Spark Of Life, Kiss Of Death For Nerve Cells
ScienceDaily - Fri, 02 Mar 2007 04:00 EST
- Injection Drug Use Fueling Spread Of HIV In Mauritius
MedicalNewsToday - Mon, 26 Feb 2007 09:00 EST
- Calcium And Vitamin D Supplements Don't Affect Heart Disease Risk, Study Suggests
ScienceDaily - Tue, 20 Feb 2007 04:00 EST
- Calcium, vitamin D boost reduces fractures
MSNBC - Wed, 14 Feb 2007 09:27 EST
- Calcium Lowers Cardiovascular Risk In People On A Weight Loss Program, Study Finds
ScienceDaily - Wed, 14 Feb 2007 04:00 EST
Clinical Trials
1 - 5 of 641 more >>
- A Study to Evaluate the Effects of Two Vitamin D Analogs, Zemplar® Injection and Hectorol® Injection, on Intestinal Absorption of Calcium in Patients With Stage 5 Chronic Kidney Disease
ClinicalTrials.gov Identifier: NCT00257920 - Recruiting
Stage 5 Chronic Kidney Disease (CKD); Secondary Hyperparathyroidism
- Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer
ClinicalTrials.gov Identifier: NCT00022087 - Active, not recruiting
Breast Cancer; Osteoporosis
- Calcium Absorption and Retention From Marine Products
ClinicalTrials.gov Identifier: NCT00393289 - Active, not recruiting
Calcium Metabolism
- Supplemental Calcium in Overweight People
ClinicalTrials.gov Identifier: NCT00030238 - Active, not recruiting
Obesity
- TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer
ClinicalTrials.gov Identifier: NCT00057720 - Active, not recruiting
Ovarian Neoplasms

Not Signed In -

